Speaker Series 4-year analysis of MURANO study in CLL

This is a review of the four-year analysis of the MURANO study of venetoclax–rituximab in relapsed/refractory chronic lymphocytic leukaemia.
Independent commentary is provided by Professor John Seymour AM, a clinical haematologist and Associate Director of Clinical Research at the Peter MacCallum Centre, and the Director of the Department of Haematology of the Peter MacCallum Cancer Centre & the Royal Melbourne Hospital in Melbourne.

Please login below to download this issue (PDF)